- Pluristem Therapeutics (PSTI) Provides Update on Clinical Status of IC Trials
- Pluristem Therapeutics (PSTI +2.15%) suspends trials in Germany for its ... - Seeking Alpha
- PLURISTEM THERAPEUTICS INC. : Life of Cancer Patient Suffering from Bone ... - 4-traders (press release)
- Pluristem Therapeutics Inc. (NASDAQ:PSTI) Investor Alert: Investigation over ... - SBWire (press release)
- PLURISTEM THERAPEUTICS INC. : Pluristem to Deliver Two Presentations ... - 4-traders (press release)
- Setback for Pluristem Therapeutics - Zacks.com
- Pluristem Therapeutics: FDA Places Trial of Investigational Treatment for Calf ... - Wall Street Journal
- Set back for Pluristem: FDA Hold
- PLURISTEM THERAPEUTICS INC. : Pluristem to Present at FDA Symposium - 4-traders (press release)
- UPDATE: MLV Initiates Pluristem Therapeutics at Buy on Unique Cell Therapy ... - Benzinga
- Pluristem Therapeutics (PSTI) to Present at FDA Symposium
- Pluristem Therapeutics (PSTI) Welcomes Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and Nuclear Safety and the Chairman of the Charite Berlin-Brandenburg Center for Regenerative Therapies
- Pluristem Therapeutics Incorporated - Newswise - Newswise (press release)
- PLURISTEM THERAPEUTICS INC. : Preclinical Research Shows PLX Cells May ... - 4-traders (press release)
- Pluristem Therapeutics (PSTI) Release: Preclinical Research Shows PLX Cells May be Effective in Treating Preeclampsia
- PLURISTEM THERAPEUTICS INC. : Pluristem and United Therapeutics Enter ... - 4-traders (press release)
- PLURISTEM THERAPEUTICS INC. : Pluristem Develops PLX-RAD Cells for Use ... - 4-traders (press release)
- Pluristem Therapeutics (PSTI) Develops PLX-RAD Cells for Use in Hematology
- PLURISTEM THERAPEUTICS INC. : Pluristem to Present at Needham ... - 4-traders (press release)
- PLURISTEM THERAPEUTICS INC. : Pluristem's PLX-PAD Cells' Safety in ... - 4-traders (press release)
- United Therapeutics' Second PAH Stumble Emphasizes The Need For ... - Seeking Alpha
- PLURISTEM THERAPEUTICS INC. : Third Party Research Study Demonstrates ... - 4-traders (press release)
- Stocks to Eyes On: Lumber Liquidators, Pluristem Therapeutics, Vocus, Unisys - SBWire (press release)
- Pluristem Therapeutics (PSTI -1.4%) expands its presence in the orthopedic and ... - Seeking Alpha
- Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine - NASDAQ (press release)
- United Therapeutics Receives Regulatory Approval to Commence Phase I Study ... - NASDAQ (press release)
- Pluristem Therapeutics (PSTI) Says United Therapeutics Receives OK for ... - StreetInsider.com (subscription)
- United Therapeutics Receives Regulatory Approval to Commence Phase I Study ... - GlobeNewswire (press release)
- TOP 10 GAINING STOCKS Today – CollabRx, Dot Hill Systems, Alcatel-Lucent ... - Pentagon Post
- Jefferies Starts Pluristem Therapeutics (PSTI) at Hold - StreetInsider.com (subscription)
- Pluristem Therapeutics (PSTI) says the first group of six patients have ... - Seeking Alpha
- UPDATE: Jefferies Initiates Pluristem Therapeutics at Hold on Balanced Risk ... - Benzinga
- Pluristem Therapeutics Receives New Coverage from Analysts at Jefferies ... - Zolmax
- Mid Day Stock Gainers: Sangamo Biosciences, Pluristem Therapeutics Inc ... - SBWire (press release)
- United Therapeutics Moves Forward Towards a Phase I Study of Pluristem's PLX ... - MarketWatch (press release)
- Pluristem Therapeutics, Inc. Announces Its Sr. VP of Corporate Development ... - Marketwire (press release)
- PLURISTEM THERAPEUTICS INC. : Pluristem Receives FDA Orphan Drug ... - 4-traders (press release)
- Notable Movers: Pluristem Therapeutics Inc, General Electric Company, Calgon ... - SBWire (press release)
- Pluristem Therapeutics (PSTI) Obtains Orphan Drug Status for Aplastic Anemia Treatment
- Pluristem Therapeutics Moving Into New State-of-the-art GMP Facility - NASDAQ
- CORRECTING AND REPLACING -- Pluristem CEO to Participate in Key ... - MarketWatch (press release)
- Pluristem CEO to Participate in Key Roundtable Discussion at the 8th Annual ... - MarketWatch (press release)
- Pluristem Therapeutics Inc.-Product Pipeline Review-2012 New Report - SBWire (press release)
- Pluristem Therapeutics Moving Into New State-of-the-art GMP Facility - RTT News
- PLURISTEM THERAPEUTICS INC. : Pluristem Updates Cell Manufacturing ... - 4-traders
- Pluristem Therapeutics (PSTI) Updates Cell Manufacturing Industry on Its Proprietary 3D Cell Expansion Technology at Industry Conference
- Pluristem Therapeutics (PSTI) climbs 6.5% after the developer of placenta ... - Seeking Alpha
- US HOT STOCKS: Lululemon, Pluristem Therapeutics, Radisys, ViroPharma -2- - Wall Street Journal
- Pluristem Therapeutics (PSTI) Receives Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Germany
- "Pluristem Therapeutics Inc. - Product Pipeline Review - 2012" Now Available ... - SBWire (press release)
- PLURISTEM THERAPEUTICS INC. : Pluristem's CEO Letter to Shareholders - 4-traders
- Pluristem Initiates Final Validation of New Manufacturing Facility - PharmaLive (press release) (subscription)
- PLURISTEM THERAPEUTICS INC. : Pluristem Initiates Final Validation of New ... - 4-traders
- PLURISTEM THERAPEUTICS INC. : The Rosen Law Firm Announces ... - 4-traders
- The Rosen Law Firm Announces Investigation Of Securities Claims Against ... - TheStreet.com (press release)
- The Rosen Law Firm Announces Investigation of Securities Claims Against ... - Fort Mills Times
- PLURISTEM THERAPEUTICS INC. : Pluristem to Present at Oppenheimer 23rd ... - 4-traders
- PLURISTEM THERAPEUTICS INC. : Pluristem Joins Both the TA-75 and TA-100 ... - 4-traders
- Pluristem Advances Its Intramuscular Hematology Program; Assembles Clinical ... - NASDAQ
- Are Short-Sellers Onto Something at Pluristem Therapeutics? - Motley Fool
- Orphan Status Update from Pluristem - Zacks.com
- Pluristem Therapeutics (PSTI) Reports Status Of Orphan Drug Application For ... - iStockAnalyst
- PLURISTEM THERAPEUTICS INC. : Pluristem Reports Status of Orphan Drug ... - 4-traders
- Pluristem to Initiate a Phase I/II Clinical Trial in Muscle Injury - NASDAQ
- Pluristem Therapeutics (PSTI) to Initiate a Phase I/II Clinical Trial in Muscle Injury
- Report slams 'Bloomberg' over article on Pluristem girl's death [Globes, Tel ... - Equities.com
- Pluristem: Second Patient With 'Life-Saving' Cells Died - Businessweek
- Girl Dies as Pluristem Sells on Gains With Miracle Cells: Health - San Francisco Chronicle
- Girl Dies as Pluristem Sells on Gains With Miracle Cells - Businessweek
- Pluristem Completes Large Scale Cell Therapy Formulation for Commercial and ... - Equities.com
- Pluristem Completes Large Scale Cell Therapy Formulation for Commercial and Clinical Trial Use
- Pluristem Standardizes Stem Cell Therapy, Opening Door To The Future Of ... - Seeking Alpha
- Pluristem Achieves Milestone Towards Completion of Its New GMP ... - NASDAQ
- Pluristem's PLX Cells Reduce Fibrotic Processes - Equities.com
- FDA proposed fast-track for critical patients could benefit Pluristem [Globes ... - Equities.com
- Pluristem's PLX Cells Reduce Fibrotic Processes - NASDAQ
- Pluristem CEO: Little chance of failure [Globes, Tel Aviv, Israel] - Equities.com
- Pluristem Issues Letter to Shareholders Highlighting Significant Achievements ... - NASDAQ
- Pluristem Develops Point-of-Care Thawing Device for PLX Cells - NASDAQ
- Pluristem Therapeutics signs Fisher BioServices as distributor for preclinical ... - OutSourcing-Pharma.com
- Pluristem Selects Fisher BioServices as Worldwide Dispatch Distributor of Its ... - NASDAQ
- WEALTHMAKERS.COM: Issues Research Reports on AMAT, CTIC, JIVE, MRVL ... - Equities.com
- Jerusalem Post Newspaper Highlights Pluristem Therapeutics' Life Saving ... - Reuters
- Pluristem shares skid on equity offering - Businessweek
- Pluristem Announces Closing of Public Offering of Common Stock and Warrants ... - NASDAQ
- Pluristem selling $32M in stock and warrants - Businessweek
- PropThink: Pluristem Raises Money Through Equity Offering; Will Momentum ... - Reuters
- Pluristem Announces Proposed Public Offering of Common Stock and Warrants ... - NASDAQ
- Pluristem: Third Patient Successfully Treated with its Cells - Wall Street Journal
- US HOT STOCKS: Pep Boys, Pluristem Therapeutics, US Airways, Verso Paper -3- - Businessweek
- DS Brokerage sees 90 percent upside for Pluristem [Globes, Tel Aviv, Israel] - Equities.com
- DS Brokerage sees 90% upside for Pluristem - Globes
- Orphan Drug Designation for Pluristem's Aplastic Anemia Treatment Could Open ... - Reuters
- Pluristem Files for Orphan Drug Status With US FDA for Use of PLX Cells in ... - NASDAQ
- Pre-Market Movers (Molycorp, Best Buy, Aixtron, Nokia, Sterlite Industries ... - International Business Times
- Pluristem Therapeutics Shoots From The Hip, Moving Toward The Sports ... - Seeking Alpha
- Pluristem to Begin IC Phase II Trial - Analyst Blog - NASDAQ
- Pluristem begins Phase II artery-disease clinical trial [Globes, Tel Aviv, Israel] - Equities.com
- Pluristem Commences US FDA Phase II Clinical Trial for Intermittent Claudication - NASDAQ
- Healthcare Review: Invacare, Pluristem & Geron Jump, ImmunoCellular ... - Reuters
- Pluristem Gets Green Light in India - Analyst Blog - NASDAQ
- Breaking Down Pluristem's Buerger's Disease Trial News - Reuters
- Pluristem obtains Indian Phase II trial approval [Globes, Tel Aviv, Israel] - Equities.com
- Pluristem Receives Approval From Indian Ministry of Health for Use of PLX ... - NASDAQ
- Cato Research, Pluristem collaborate on IC phase II trial - Pharmaceutical Business Review
- Pluristem Moves Intermittent Claudication Indication Forward in Europe Through ... - NASDAQ
- Ahead of the Bell: Pluristem Therapeutics climbs - CBS News
- Pluristem PLX Cell Treatment Saves Cancer Patient - RedOrbit
- Pluristem PLX cells turn around near fatal bone marrow failure - FierceDrugDelivery
- Pluristem says cells save second patient with bone marrow failure - EmpowHer
- Ahead of the Bell: Pluristem Therapeutics climbs - Businessweek
- Another (2nd) patient saved by PSTI
- Osiris Therapeutics and Pluristem Therapeutics Showing Impressive Growth as ... - SYS-CON Media (press release)
- Pluristem Therapeutics' New Indication for Pulmonary and Lung Disorders ... - Reuters
- Maxim Initiates Coverage of Pluristem Therapeutics Inc. with a Buy Rating and ... - MarketWatch (press release)
- Pluristem, NIH to study stem cells to treat radiation syndrome - Reuters
- Pluristem Wins NIH Backing for Radiation-Exposure Study - Businessweek
- Pluristem, NIH to study stem cells to treat radiation syndrome - Reuters
- Pluristem Therapeutics Inc. gets NIH Invitation
- Maxim Initiates Coverage of Pluristem Therapeutics Inc. with a Buy Rating and ... - Reuters
- Pluristem Therapeutics Set to Enter Bone Marrow Disease Market as it is ... - MarketWatch (press release)
- Pluristem Focuses On Therapeutic Cells Delivered Intramuscularly - RedOrbit
- Equity Briefing: Pluristem Therapeutics' Peripheral Artery Treatment Likely to ... - Reuters
- Pluristem Therapeutics' Answer To Big Pharma's Question: What Do We Do Now? - Seeking Alpha
- Pluristem Partners With CPC Clinical Research for Peripheral Artery Disease ... - MarketWatch (press release)
- Medistem the competitor has Major news today !! Remember Meds has the stem cell patents !
- Pluristem's Unique Therapy Primed to Replace Blockbuster Drugs for Treating ... - Reuters
- Pluristem's Unique Therapy Primed to Replace Blockbuster Drugs for Treating Peripheral Arterial Disease
- Medistem Placental patent
- Medistem looks to own the patent for placental stem cells an expansion of stem cells patent and a lot more!
- Pluristem Pioneering Intramuscular Placenta-Based Cell Therapies - Seeking Alpha
- Pluristem and Medistem mirror image companies ,both doing the same thing, who will be first ?
- Pluristem in Talks With Drugmakers on PLX-PAD Licensing - Businessweek
- Pluristem Therapeutics' Cell Therapy Broadens Addressable ... - MarketWatch (press release)
- Pluristem Director Dr. Liat Flaishon Interviewed on CorporateProfile ... - Einnews Portugal
- Pluristem Director Dr. Liat Flaishon Interviewed on CorporateProfile ... - MarketWatch (press release)
- Pluristem Director Dr. Liat Flaishon Interviewed on CorporateProfile.com
- Pluristem to Present at Jefferies Global Healthcare Conference - GlobeNewsWire (press release)
- Pluristem to Present at Jefferies Global Healthcare Conference - Virtual-Strategy Magazine
- Pluristem to Present at Jefferies Global Healthcare Conference - NASDAQ
- Pluristem's CEO Letter to Shareholders - MarketWatch (press release)
- Equity Briefing : Pluristem's PLX cells may change bone marrow transplantation ... - Reuters
- Needham & Company Starts Pluristem Therapeutics (PSTI) at Buy; Leading Cell ... - StreetInsider.com (subscription)
- Updated: Pluristem Therapeutics' New Indication May Boost Company Valuation - The Mumbai Times
- FDA Petition
- Pluristem Therapeutics' New Indication May Boost Company Valuation - Seeking Alpha
- Cardiac Function in Pre-Clinical Diabetic Diastolic Heart Failure Subjects ... - MarketWatch (press release)
- Cardiac Function in Pre-Clinical Diabetic Diastolic Heart Failure Subjects Improved by Pluristem's PLX Cells Study Was Conducted Under the European Commission's Seventh Framework Program (FP7) Collaboration
- Pluristem stem cells save girl's life - Chicago Tribune
- Amyris, Cost Plus, Pluristem Therapeutics: U.S. Equity Movers - San Francisco Chronicle
- Compassionate Use of Pluristem's PLX Cells Saves the Life of a Child After ... - MarketWatch (press release)
- Compassionate Use of Pluristem's PLX Cells Saves the Life of a Child After Bone Marrow Transplantation Failure
- Stem cell co Pluristem awarded $3.1m chief scientist grant - Globes
- Pluristem Heads for Two-Month High on $3.2 Million Israeli Grant - Bloomberg
- FDA Clears Pluristem's Phase II Clinical Trial In Intermittent Claudication - RTT News
- Pluristem Receives US FDA Clearance for Phase II Clinical Trial in ... - MarketWatch (press release)
- Pluristem Takes A Huge Step For The Entire Cell Therapy Sector - Seeking Alpha
- Pluristem gets US FDA clearance to begin phase II trial in Intermittent ... - pharmabiz.com
- Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial in ... - MarketWatch (press release)
- FDA Clears Pluristem's Phase II Clinical Trial In Intermittent Claudication - NASDAQ
- Pluristem Therapeutics to Present at Three Conferences in April - MarketWatch (press release)
- In 2020, Pluristem Therapeutics' PLX-PAD Will Earn Decision Resources ... - EON: Enhanced Online News (press release)
- Pluristem Says Its PLX Cells Effective In Treating AMI In Animal - Quick Facts - RTT News
- Pluristem Begins Up Scaling Its PLX Cell Bioreactors - MarketWatch (press release)
- Pluristem Therapeutics' CEO Quarterly Update - MarketWatch (press release)
- $43mm in cash and building own facility & starting p.ii in germany woooow
- Pluristem to Expand Research & Development of Radiation Exposure Treatment
- Goldman Research sees 50% upside for Pluristem
- Psti
- Pluristem sees positive data from stem cell trials
- Do you beleive in Cell Therapy yet?
- WOW Big time---------Stem cell co Pluristem files to raise $150m on Nasdaq
- Pluristem's PLX Cells Found to Have Potential to Treat Acute Radiation Syndrome (shares up 7%)
- Present at Leading U.S. Industry Conferences
- FDA approves Pluristem’s Buerger’s disease stem cell treatment
- new Israeli stem cells facility
- Pluristem Therapeutics Inc. (PSTI) reached an exclusive licensing agreement with biotechnology company United Therapeutics Corp.
- OT: PSTI........we need such agreement!!!!!
- OT: PSTI........we need such agreement!!!!!
- that the way...i like it!!!!!!!
- CEO gets the faithful jumpin!
- PSTI's New website LOOK
- Psti
- Pluristem, Hadassah to work on stem cell cure for radiation damage
- Israeli bio-tech firm touts stem cell treatment formultiple sclerosis